HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-rel...

Full description

Saved in:
Bibliographic Details
Main Authors LEWIS, DIANA Y, SOARES, CHRISTOPHER J, MACK, CHRISTINE M, LEVY, ODILE ESTHER, D'SOUZA, LAWRENCE J, HANLEY, MICHAEL R, GHOSH, SOUMITRA S, JODKA, CAROLYN M, PARKES, DAVID G
Format Patent
LanguageEnglish
French
Published 25.08.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. L'invention concerne de nouveaux polypeptides hybrides pouvant être choisis, utiles en tant qu'agents de traitement et de prévention des maladies et des troubles métaboliques pouvant être atténués par la régulation du niveau de glycémie, du niveau d'insuline et/ou de la sécrétion d'insuline, tels que le diabète et les états liés au diabète. Ces maladies et troubles comprennent, entre autres, l'hypertension, la dyslipidémie, les maladies cardio-vasculaires, les troubles alimentaires, la résistance à l'insuline, l'obésité, le diabète sucré de tout type, notamment de type 1 et de type 2, et le diabète gestationnel.
Bibliography:Application Number: WO2005US04178